To provide long term capital appreciation.
Name | % Net Assets |
---|---|
BG Group | 5.0% |
Gilead Sciences | 3.5% |
StatoilHydro ASA | 2.9% |
AXA S.A. | 2.8% |
Credit Suisse Group | 2.8% |
Itau Unibanco Banco Multiplo S.A. ADS | 2.7% |
GlaxoSmithKline | 2.6% |
Astrazeneca | 2.6% |
Lloyds Banking Group | 2.6% |
Merck & Co. | 2.6% |
Key | % Net Assets |
---|---|
BG Group | 5.0% |
Gilead Sciences | 3.5% |
StatoilHydro ASA | 2.9% |
AXA S.A. | 2.8% |
Other | 85.8% |
Date | 21-Nov-2024 |
---|---|
NAV | 308.09p |
Currency | GBP |
Change | 1.01p |
% | 0.33% |
YTD change | 22.06p |
YTD % | 7.71% |
Fund Inception | 19/02/2001 |
---|---|
Fund Manager | Derek Lygo |
TER | 0.84 (31-Jan-2013) |
Minimum Investment | |
---|---|
Initial | £500000 |
Additional | n/a |
Savings | £50 |
Charges | |
---|---|
Initial | n/a |
Annual Mang't | 0.75% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.02 |
Sharpe ratio | 0.04 |
You are here: research